Nanotechnology for Psoriasis Therapy
- 19 Downloads
Purpose of Review
To summarize the use of nanotechnology-based drug delivery systems for psoriasis therapies, focusing on recent studies of treatment efficacy in humans and murine models.
Both topical and oral psoriasis medications, in addition to alternative psoriasis therapies and siRNAs targeting genes involved in the pathogenesis of psoriasis, have been incorporated into nanocarriers. Numerous studies demonstrate that nanocarriers can enhance the efficacy and reduce side effects of their included drugs through increased skin retention, sustained release, and decreased systemic absorption. However, the number of studies in humans is limited and while the short-term use of nanocarriers appears safe, long-term outcomes are unknown. Additionally, few studies compare different types of nanocarriers, making it difficult to recommend which types of nanocarriers are the best.
While recent research has demonstrated the benefit of nanotechnology-based drug delivery systems for psoriasis, more research, especially in humans, is needed to optimize drug-loaded nanocarriers for clinical use.
KeywordsPsoriasis Nanotechnology Transdermal drug delivery Nanomedicine Nanocarriers
Compliance with Ethical Standards
Conflict of Interest
The authors of this paper have no conflicts of interest to declare.
Human and Animal Rights
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643–59.PubMedGoogle Scholar
- 3.Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010;62:114–35.PubMedGoogle Scholar
- 5.Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61:451–85.PubMedGoogle Scholar
- 9.Wan T, Pan W, Long Y, Yu K, Liu S, Ruan W, et al. Effects of nanoparticles with hydrotropic nicotinamide on tacrolimus: permeability through psoriatic skin and antipsoriatic and antiproliferative activities. Int J Nanomed. 2017;12:1485–97.Google Scholar
- 12.• Raza K, Singh B, Lohan S, Sharma G, Negi P, Yachha Y, et al. Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity. Int J Pharm. 2013;456:65–72 Compared skin retention and anti-psoriatic efficacy of tretinoin-loaded liposomes, ethosomes, solid lipid nanoparticles, and nanostructured lipid carriers in a murine model. This is one of the few studies comparing carriers against each other rather than to marketed products. The liposomes and nanostructured lipid carriers led to the highest tretinoin skin retention and efficacy.PubMedGoogle Scholar
- 13.•• Abdelgawad R, Maha N, Mofta N, Hamza M. Phospholipid membrane tubulation using ceramide doping “cerosomes”: characterization and clinical application in psoriasis treatment. Eur J Pharm Sci : official journal of the European Federation for Pharmaceutical Sciences. 2017;101:258–68 Vesicular carriers including both tazarotene and ceramide improved psoriasis symptoms more than both commercial tazarotene gel and tazarotene-loaded vesicular carriers without ceramides in a randomized, controlled trial with 20 patients. This is one of the few trials with human participants. Google Scholar
- 14.•• Kumar R, Dogra S, Amarji B, Singh B, Kumar S, null S, et al. Efficacy of novel topical liposomal formulation of cyclosporine in mild to moderate stable plaque psoriasis: a randomized clinical trial. JAMA Dermatol. 2016;152:807–15 Cyclosporine-loaded liposomes were used to treat 38 patients in this double-blind, randomized controlled trial. Cyclosporine-liposomes resulted in higher plaque clearance than a commercial cyclosporine cream but lower clearance than clobetasol propionate. No systemic cyclosporine absorption was detected with blood sampling in patients treated with cyclosporine-liposomes. PubMedGoogle Scholar
- 18.Patel R, Singh SK, Singh S, Sheth N, Gendle R. Development and Characterization of Curcumin Loaded Transfersome for Transdermal Delivery. J Pharm Sci Res. 2009;1(4):71–80.Google Scholar
- 23.Namdeo A, Jain N. Niosomes as drug carriers. Indian J Pharm Sci. 1996;58:41–6.Google Scholar
- 24.Abu Hashim II, Abo El-Magd NF, El-Sheakh AR, Hamed MF, Abd El-Gawad AE-GH. Pivotal role of Acitretin nanovesicular gel for effective treatment of psoriasis: ex vivo-in vivo evaluation study. Int J Nanomed. 2018;13:1059–79.Google Scholar
- 27.Marepally S, Boakye CHA, Patel AR, Godugu C, Doddapaneni R, Desai PR, et al. Topical administration of dual siRNAs using fusogenic lipid nanoparticles for treating psoriatic-like plaques. Nanomedicine (London). 2014;9:2157–74.Google Scholar
- 28.Thakur A, Walia MK, Kumar SLH. Nanoemulsion in enhancement of bioavailability of poorly soluble drugs: a review. Pharmacophore. 2013;4(1):15–25.Google Scholar
- 29.Musa SH, Basri M, Fard Masoumi HR, Shamsudin N, Salim N. Enhancement of physicochemical properties of nanocolloidal carrier loaded with cyclosporine for topical treatment of psoriasis: in vitro diffusion and in vivo hydrating action. Int J Nanomedicine. 2017;12:2427–41.PubMedPubMedCentralGoogle Scholar
- 30.• Kaur A, Katiyar SS, Kushwah V, Jain S. Nanoemulsion loaded gel for topical co-delivery of clobitasol propionate and calcipotriol in psoriasis. Nanomedicine. 2017;13:1473–82 Examined efficacy of a nanogel including both clobetasol propionate and calcipotriol highlighting the ability to combine multiple drugs in nanocarriers. The drug-loaded nanogel led to increased drug retention and anti-psoriatic efficacy compared to free drugs.PubMedGoogle Scholar
- 32.Alam MS, Ali MS, Alam N, Siddiqui MR, Shamim M, Safhi MM. In vivo study of clobetasol propionate loaded nanoemulsion for topical application in psoriasis and atopic dermatitis. Drug Invention Today. 2013;5:8–12.Google Scholar
- 41.• Nemati H, Ghahramani M-H, Faridi-Majidi R, Izadi B, Bahrami G, Madani S-H, et al. Using siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation in psoriasis. J Control Release. 2017;268:259–68 EGFR siRNA was conjugated to gold nanoparticles and efficacy was examined in an imiquimod-induced murine model. Use of the EGFR siRNA-AuNPs led to reduced T cell markers and epidermal thickness compared to nonsense siRNA-AuNPs and free EGFR siRNA, respectively. This highlights the success of siRNA treatment for psorasis, meaning that many other genes involved in psoriasis could also be targeted. PubMedGoogle Scholar
- 43.Chamcheu JC, Siddiqui IA, Adhami VM, Esnault S, Bharali DJ, Babatunde AS, et al. Chitosan-based nanoformulated (−)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis. Int J Nanomedicine. 2018;13:4189–206.PubMedPubMedCentralGoogle Scholar
- 45.Kabanov AV, Vinogradov SV. Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. Angew Chem Int Ed. 2009;48:5418–29.Google Scholar
- 46.• Divya G, Panonnummal R, Gupta S, Jayakumar R, Sabitha M. Acitretin and aloe-emodin loaded chitin nanogel for the treatment of psoriasis. Eur J Pharm Biopharm. 2016;107:97–109 Created nanogels loaded with acitretin and a complementary therapy, aloe-emodin (an Aloe vera extract). Application of these two nanogels produced greater efficacy than a commercial tacrolimus cream showing that you can also apply multiple nanocarrier formulations, in addition to combining multiple drugs within a nanocarrier. PubMedGoogle Scholar
- 48.• Panonnummal R, Jayakumar R, Anjaneyan G, Sabitha M. In vivo anti-psoriatic activity, biodistribution, sub-acute and sub-chronic toxicity studies of orally administered methotrexate loaded chitin nanogel in comparison with methotrexate tablet. Int J Biol Macromol. 2018;110:259–68 A lower dose of oral methotrexate included in chitin nanogels reduced psoriasis symptoms in a murine model without causing liver and lung toxicities that were seen with higher doses of methotrexate nanogels and free methotrexate. PubMedGoogle Scholar
- 49.Monteiro-Riviere NA. Skin penetration of engineered nanomaterials. In: Nasir A, Friedman A, Wang S, editors. Nanotechnology in dermatology. New York, NY: Springer New York; 2013. p. 51–61.Google Scholar
- 51.Wohlrab J, Goebel A, Scherer D, Bingham D, Newbert R A topical tacrolimus microemulsion for plaque-type psoriasis therapy. Drug Development & Delivery. 2012; June.Google Scholar
- 55.Draelos ZD. Enhancement of topical delivery with Nanocarriers. In: Nasir A, Friedman A, Wang S, editors. Nanotechnology in dermatology. New York, NY: Springer New York; 2013. p. 87–93.Google Scholar
- 66.Zanolli M. Phototherapy treatment of psoriasis today. J Am Acad Dermatol. 2003;49:78–86.Google Scholar
- 68.Shaikh IM, Jadhav KR, Kadam VJ. Lecithin organogels in enhancing skin delivery of drugs. In: Dragicevic N, Maibach HI, editors. Percutaneous penetration enhancers chemical methods in penetration enhancement: drug manipulation strategies and vehicle effects. Berlin, Heidelberg: Springer Berlin Heidelberg; 2015. p. 299–313.Google Scholar
- 71.Jeffes EW, McCullough JL, Pittelkow MR, McCormick A, Almanzor J, Liu G, et al. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol. 1995;104:183–8.PubMedGoogle Scholar
- 83.Geusens B, Van Gele M, Braat S, De Smedt SC, Stuart MCA, Prow TW, et al. Flexible nanosomes (SECosomes) enable efficient siRNA delivery in cultured primary skin cells and in the viable epidermis of ex vivo human skin. Adv Funct Mater. 2010;20:4077–90.Google Scholar